Roivant Launches Cytovant Sciences to Collaborates with Medigene for the Development of Cellular Therapies in Asia

 Roivant Launches Cytovant Sciences to Collaborates with Medigene for the Development of Cellular Therapies in Asia

Roivant Launches Cytovant Sciences to Collaborates with Medigene for the Development of Cellular Therapies in Asia

Shots:

  • Medigene to receive $10M upfront, $1B as development, regulatory, and commercial milestones & royalties on sales of four products in multiple indications. Cytovant to get exclusive development & commercialization rights for Medigene’s TCR therapy for NY-ESO-1 and Dendritic cell (DC) vaccine targeting WT-1 & PRAME in Greater China, South Korea, and Japan
  • Cytovant and Medigene have also entered into a research agreement for T-cell receptor (TCR) immunotherapies for two additional targets. Medigene to take care of generation and delivery of TCR constructs using TCR platform, with all R&D cost reimburse by Cytovant
  • T cells are modified for adoptive T cell therapy with tested T cell receptors (TCR-Ts) which usually recognize and kill cancer or tumor cells 

Click here to read full press release/ article | Ref: Roivant | Image: Finsmes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post